RxDoctor Payments Data

Amy Gilbert

Family · Woodbury, MNNPI 1780461681

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (44.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Sanofi accounts for 70.7% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $5,517, more than ten times the $145 reported in 2023. Among family clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,482in general payments, 2019–2025

Across 44 payments — averaging $170.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$5K
  • Genentech USA, Inc.$2K
  • AstraZeneca$64
  • Bristol Myers Squibb$62
  • Biogen$60
  • Octapharma USA, Inc.$57
  • plus $378 from 13 others
$2,435in research payments, 2019–2025

Across 13 payments — averaging $187.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$2K

What the payments were for

  • Consulting fees$1,42519%
  • Speaking & faculty fees$3,32244%
  • Travel & lodging$1,86825%
  • Food & beverage$86712%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,482 in reported general payments places this provider in the 95th percentile of 1,121 family providers in Minnesota.

See all family providers in Minnesota

Medicare billing

Part B allowed, 2024
$2,003,626
Medicare patients
156
Services billed
57,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate12$72,047
Baclofen93$3,791
Dalfampridine ErDalfampridine15$3,178
Gabapentin35$1,197
Modafinil21$1,094
Pregabalin53$1,073
Clonazepam65$731
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$550
Trazodone Hcl39$505
Fluoxetine Hcl13$408
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine18$352
Tizanidine Hcl33$278
Diazepam38$234
Alprazolam11$163

Paid to pharmacies, not to this prescriber.

Other family in Woodbury

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →